MedTrace Logo

To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study

NCT00870038 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-07-22

No results posted yet for this study

Summary

The investigators sought to discover which one of the following strategies is the safest for patients undergoing percutaneous coronary intervention: paclitaxel-coated balloon+Genous stent; Genous stent; drug eluting stent (paclitaxel).

Conditions

  • Angioplasty, Transluminal, Percutaneous Coronary
  • Percutaneous Coronary Intervention

Interventions

DEVICE

Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent

Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent

DEVICE

Percutaneous coronary intervention: Uncoated balloon + Genous stent

Predilatation with uncoated balloon, the stenting with Genous stent.

DEVICE

Percutaneous coronary intervention: Drug eluting stent (Taxus stent)

Predilatation with uncoated balloon, the placement of a Taxus stent.

Sponsors & Collaborators

  • Ospedale della Misericordia

    lead OTHER

Principal Investigators

  • Bernardo Cortese, MD, FESC · Ospedale Maggiore Policlinico, Milano, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-08-31
Completion
2012-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00870038 on ClinicalTrials.gov